Newco XO1 debuts with $11M from Index

Index Ventures launched XO1 Ltd. (Cambridge, U.K.) with $11 million in a series A round to develop ichorcumab, a preclinical synthetic mAb against the exosite 1 region of thrombin licensed from the University of Cambridge. The virtual newco plans to start clinical testing of the anticoagulant in volunteers within two years. Index's David Grainger is interim CEO and the firm's Kevin Johnson joined XO1's board. Andy Walsh from Cambridge Enterprise, the university's commercialization arm, also joined XO1's board. ...